While the drugmaker provided few details on the plan, a new restructuring program is meant to align its global manufacturing to reflect changes in the business.
The CDMO’s retroviral vector will be used to manufacture AvenCell’s investigational dual-targeted therapy for B cell malignancies and autoimmune diseases.
